Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07636863 · ClinicalTrials.gov registry record
Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 200
- Enrollment target
NCT07636863 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 200 participants.
The verdict
NCT07636863 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
This study will review medical records of adults with cancer who received nivolumab either as an intravenous (IV) infusion or as a subcutaneous (under the skin) injection in community oncology clinics in the United States. The study will describe who receives each type of treatment, how the treatments are used, and selected safety events such as reactions at the injection or infusion site and infections.
Interventions
- DRUG Nivolumab
- COMBINATION_PRODUCT Subcutaneous nivolumab combined with hyaluronidase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-08-21 |
| Est. Completion | 2026-03-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07636863
The ClinicalTrials.gov registry entry for NCT07636863 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT07636863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07636863 about?
NCT07636863 is a clinical study titled "Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig". This study will review medical records of adults with cancer who received nivolumab either as an intravenous (IV) infusion or as a subcutaneous (under the skin) injection in community oncology clinics in the United States. The study will describe who receives each type of treatment, how the treatmen...
What is the current status of trial NCT07636863?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2025-08-21. Estimated completion is 2026-03-27.
What interventions are being tested in trial NCT07636863?
The interventions under investigation include: Nivolumab (DRUG), Subcutaneous nivolumab combined with hyaluronidase (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07636863?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.